Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Perreault, Leigh, Davies, Melanie, Frias, Juan P, Laursen, Peter Norkjaer, Lingvay, Ildiko, Machineni, Sriram, Varbo, Anette, Wilding, John PH ORCID: 0000-0003-2839-8404, Wallenstein, Signe Olrik Rytter and le Roux, Carel W (2022) Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. DIABETES CARE, 45 (10). pp. 2396-2405.

Text
DC21-1785.R1_Revised manuscript_accepted.docx - Author Accepted Manuscript
Download (144kB)

Official URL: http://dx.doi.org/10.2337/dc21-1785

Abstract

<h4>Objective</h4>This analysis of 3,375 adults with overweight/obesity across the Semaglutide Treatment Effect in People with obesity (STEP) 1, 3, and 4 trials evaluated whether more participants with prediabetes had normoglycemia after 68 weeks' treatment with once-weekly semaglutide 2.4 mg plus lifestyle intervention versus placebo and assessed changes in glucose metabolism in participants with prediabetes.<h4>Research design and methods</h4>STEP 1, 3, and 4 were phase 3, 68-week, randomized, placebo-controlled, multinational trials; STEP 4 had a 20-week semaglutide run-in and 48-week randomized period. Analyses included changes (week 0-68; before the washout period) in glycemic status (prespecified: STEP 1 and 3; post hoc: STEP 4), and in HbA1c, fasting plasma glucose (FPG), and HOMA insulin resistance (HOMA-IR) among participants with prediabetes (post hoc).<h4>Results</h4>Significantly more participants with baseline (week 0) prediabetes (n = 1,536) had normoglycemia at week 68 with semaglutide versus placebo (STEP 1, 84.1% vs. 47.8%; STEP 3, 89.5% vs. 55.0%; STEP 4, 89.8% vs. 70.4%; all P < 0.0001). Fewer participants with baseline normoglycemia had prediabetes at week 68 with semaglutide versus placebo (STEP 1, 2.9% vs. 10.9%; STEP 3, 3.2% vs. 5.8%; STEP 4, 1.1% vs. 5.0%). Semaglutide resulted in greater improvements in HbA1c, FPG, and HOMA-IR than placebo among participants with baseline prediabetes (all P < 0.01).<h4>Conclusions</h4>STEP 1, 3, and 4 collectively provide a robust assessment of the effects of semaglutide on glucose metabolism and prediabetes in a large cohort of adults with overweight/obesity while on treatment. Among participants with baseline prediabetes, 68 weeks' treatment with semaglutide versus placebo led to significant improvements in glucose metabolism and a higher likelihood of normoglycemia.

Item Type:	Article
Uncontrolled Keywords:	Humans, Diabetes Mellitus, Type 2, Prediabetic State, Insulin Resistance, Obesity, Blood Glucose, Hypoglycemic Agents, Double-Blind Method, Adult, Overweight, Glucagon-Like Peptides, Glycated Hemoglobin
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	08 Aug 2022 07:59
Last Modified:	16 Feb 2023 19:48
DOI:	10.2337/dc21-1785
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3160451